Skip to main content

How long should an episode of depression be treated for and at what dose of antidepressants?

Author/s
Andre Tylee, Jeremy Broadhead
Citation
Issue 5 Winter 2018
CEPiP.2018.1.101-104
Abstract

Current depression guidelines are reviewed; these recommend the continuation of antidepressants at the dose that achieved response for at least a further six months, depending on patient circumstances and previous history. The dose can then be reduced gradually: the more slowly the reduction, the less likely withdrawal effects will be. If severe withdrawal symptoms occur, changing to fluoxetine, which has a long half-life, and decreasing this slowly is best. If the patient is at heightened risk of relapse, or if relapse would have serious consequences, the antidepressant should be continued. The duration of treatment depends both on the life situation and on the level of relapse risk, both of which need careful management. Learning opportunities for the management of depression need to be multi-professional and case-based. Consultation-liaison can be one way to achieve this when, for example, a local mental health professional can give case-based advice to the primary care team. However, the evidence base for changing GP behaviour is weak, even when GPs are involved in adapting and extending depression guidelines for local use.

References
  1. Dowrick C. Suffering, Meaning and Hope: Shifting the Focus from Depression in Primary Care. In: Wakefield JC, Demazeux S, editors. Sadness or Depression? International Perspectives on the Depression Epidemic and Its Meaning. Dordrecht: Springer Netherlands; 2016. p. 121-36. https://doi.org/10.1007/978-94-017-7423-9_9
  2. National Institute for Health and Care Excellence (NICE). Depression in adults: recognition and management: Clinical guideline [CG90]. National Institute for Health and Care Excellence (NICE); April 2018. https://doi.org/10.1007/978-1-349-94186-5_836
  3. Taylor D, Paton C, Kapur S. The Maudsley prescribing guidelines in psychiatry. 11th ed. Chichester, West Sussex: Wiley-Blackwell; 2012.              
  4. Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, Dickens C, Ferrier IN, Geddes J, Gilbody S, Haddad PM. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology. 2015 May;29(5):459-525. https://doi.org/10.1177/0269881115581093
  5. Newton-Howes G, Tyrer P, Johnson T. Personality disorder and the outcome of depression: meta-analysis of published studies. The British Journal of Psychiatry. 2006 Jan;188(1):13-20. https://doi.org/10.1192/bjp.188.1.13
  6. Moran P, Leese M, Lee T, Walters P, Thornicroft G, Mann A. Standardised Assessment of Personality–Abbreviated Scale (SAPAS): preliminary validation of a brief screen for personality disorder. The British Journal of Psychiatry. 2003 Sep;183(3):228-32. https://doi.org/10.1192/bjp.183.3.228
  7. Silva de Lima M, Moncrieff J, Soares B. Drugs versus placebo for dysthymia. Cochrane Database of Systematic Reviews. 2005(2). https://doi.org/10.1002/14651858.cd001130
  8. Depression Guideline Panel. Depression in primary care: volume 1. Detection and diagnosis. Clinical practice guideline, number 5. Rockville, MD: US Department of Health and Human Services. Public Health Service, Agency for Health Care Policy and Research. AHCPR Publication. 1993 Apr(93-0550). https://doi.org/10.1037/e369472004-001
  9. Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement. BMJ. 1992 Nov 14;305(6863):1198. https://doi.org/10.1136/bmj.305.6863.1198
  10. Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ, Wfsbp Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. The World Journal of Biological Psychiatry. 2015 Feb 17;16(2):76-95. https://doi.org/10.3109/15622975.2014.1001786
  11. Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, Parikh SV, Patten SB, Ravindran AV. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults.: Journal of Affective Disorders. 2009 Oct 1;117:S1-64. https://doi.org/10.1016/j.jad.2009.06.041
  12. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. The Lancet. 2003 Feb 22;361(9358):653-61. https://doi.org/10.1016/s0140-6736(03)12599-8
  13. Pringsheim T, Kelly M, Barbui C. Stopping antidepressants following depression. BMJ. 2016 Feb 18;352:i220. https://doi.org/10.1136/bmj.i220
  14. Tylee A, Walters P, Enright A. Trailblazers. Primary Care Mental Health. 2004 Jan 1;2(1):1-3.             
  15. Thompson C, Kinmonth AL, Stevens L, Pevele RC, Stevens A, Ostler KJ, Pickering RM, Baker NG, Henson A, Preece J, Cooper D. Effects of a clinical-practice guideline and practice-based education on detection and outcome of depression in primary care: Hampshire Depression Project randomised controlled trial. The Lancet. 2000 Jan 15;355(9199):185-91. https://doi.org/10.1016/s0140-6736(99)03171-2
  16. Croudace T, Evans J, Harrison G, Sharp DJ, Wilkinson E, McCann G, Spence M, Crilly C, Brindle L. Impact of the ICD-10 Primary Health Care (PHC) diagnostic and management guidelines for mental disorders on detection and outcome in primary care: cluster randomised controlled trial. The British Journal of Psychiatry. 2003 Jan;182(1):20-30. https://doi.org/10.1192/bjp.182.1.20